Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 1
3(50.0%)
6Total
Phase 2(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04932291Phase 2Completed

Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population

Role: lead

NCT07113691Phase 1Recruiting

Iadademstat + SBRT With Atezo in ES-SCLC

Role: collaborator

NCT06357182Phase 1Recruiting

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Role: collaborator

NCT05420636Phase 2Terminated

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Role: collaborator

NCT05546580Phase 1Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Role: lead

NCT03867253Phase 2Completed

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

Role: lead

All 6 trials loaded